Back to Search
JOSEPH TUSCANO, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1487639795IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
G69025(CA)G069025(CA)
Specialist
Specialist
Code: 174400000X
G069025(CA)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
UNIVERSITY OF SOUTHERN CALIFORNIA KECK SCHOOL OF MEDICINE
Class of 1989
Research & Publications (20)
B cell reductive therapy in the treatment of autoimmune diseases: a focus on monoclonal antibody treatment of rheumatoid arthritis.
PMID 16321818·Hematology·2005
6-review
B lymphocytes contribute to autoimmune disease pathogenesis: current trends and clinical implications.
PMID 12848966·Autoimmun Rev·2003
6-review
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
PMID 12511412·Blood·2003
4-observational
Phosphorylation abnormalities: NZB mice exhibit a B-cell signalling defect.
PMID 12419280·J Autoimmun·2002
7-preclinical
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD).
PMID 19306119·Invest New Drugs·2010
8-other
Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts.
PMID 19437017·Cancer Immunol Immunother·2009
7-preclinical
Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy.
PMID 19294384·Cancer Immunol Immunother·2009
7-preclinical
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
PMID 19245430·Br J Haematol·2009
3-trial
Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-hodgkin's lymphoma cells.
PMID 19237192·Leuk Res·2009
8-other
A comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients.
PMID 18823005·Cytometry B Clin Cytom·2009
4-observational
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
PMID 18606983·J Clin Oncol·2008
3-trial
Nondestructive identification of individual leukemia cells by laser trapping Raman spectroscopy.
PMID 18260656·Anal Chem·2008
8-other
Pathogenesis of aryl hydrocarbon receptor-mediated development of lymphoma is associated with increased cyclooxygenase-2 expression.
PMID 17823287·Am J Pathol·2007
7-preclinical
Multiplex analysis of intracellular signaling pathways in lymphoid cells by microbead suspension arrays.
PMID 16369048·Mol Cell Proteomics·2006
8-other
Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
PMID 16265687·J Rheumatol·2005
3-trial
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
PMID 16115934·Clin Cancer Res·2005
3-trial
Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma.
PMID 14654083·Leuk Res·2004
8-other
Applications of one-bead one-compound combinatorial libraries and chemical microarrays in signal transduction research.
PMID 12809522·Acc Chem Res·2003
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4501 X ST STE 3016
SACRAMENTO, CA 95817 - Phone
- (916) 734-5981
Quick Facts
- NPI
- 1487639795
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 3
- Locations
- 1
- Years in Practice
- 37
- Publications
- 20
Are you this provider?
Claim Your Profile